These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 32029391)
1. Is the Dream of Vascular Restoration Still Alive? A Case of 7 Years, Follow-Up After Bioresorbable Vascular Scaffold Implantation. Budassi S; Zivelonghi C; Muyldermans P; Agostoni P; Verheye S Cardiovasc Revasc Med; 2020 Nov; 21(11S):158-161. PubMed ID: 32029391 [TBL] [Abstract][Full Text] [Related]
2. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932 [TBL] [Abstract][Full Text] [Related]
3. Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions. Abizaid A; Costa RA; Schofer J; Ormiston J; Maeng M; Witzenbichler B; Botelho RV; Costa JR; Chamié D; Abizaid AS; Castro JP; Morrison L; Toyloy S; Bhat V; Yan J; Verheye S JACC Cardiovasc Interv; 2016 Mar; 9(6):565-74. PubMed ID: 27013155 [TBL] [Abstract][Full Text] [Related]
5. Impact of strut thickness on acute mechanical performance: A comparison study using optical coherence tomography between DESolve 150 and DESolve 100. Boeder NF; Dörr O; Bauer T; Mattesini A; Elsässer A; Liebetrau C; Achenbach S; Hamm CW; Nef HM Int J Cardiol; 2017 Nov; 246():74-79. PubMed ID: 28579164 [TBL] [Abstract][Full Text] [Related]
6. Randomized Comparison Between Everolimus-Eluting Bioresorbable Scaffold and Metallic Stent: Multimodality Imaging Through 3 Years. Onuma Y; Honda Y; Asano T; Shiomi H; Kozuma K; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Hanaoka KI; Tanabe K; Okada K; Kitahara H; Ono M; Kusano H; Rapoza R; Simonton C; Popma JJ; Stone GW; Fitzgerald PJ; Serruys PW; Kimura T JACC Cardiovasc Interv; 2020 Jan; 13(1):116-127. PubMed ID: 31918929 [TBL] [Abstract][Full Text] [Related]
7. One-year clinical outcomes and multislice computed tomography angiographic results following implantation of the NeoVas bioresorbable sirolimus-eluting scaffold in patients with single de novo coronary artery lesions. Wang XZ; Zhang YJ; Fu GS; Jing QM; Xu B; Han YL Catheter Cardiovasc Interv; 2018 Feb; 91(S1):617-622. PubMed ID: 29392879 [TBL] [Abstract][Full Text] [Related]
8. Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging. Tenekecioglu E; Serruys PW; Onuma Y; Costa R; Chamié D; Sotomi Y; Yu TB; Abizaid A; Liew HB; Santoso T JACC Cardiovasc Interv; 2017 Jun; 10(11):1115-1130. PubMed ID: 28527768 [TBL] [Abstract][Full Text] [Related]
9. The DESolve Demola P; Meucci F; Stolcova M; Mario CD; Mattesini A Future Cardiol; 2021 Sep; 17(6):945-951. PubMed ID: 33507091 [TBL] [Abstract][Full Text] [Related]
10. A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents. Han Y; Xu B; Fu G; Wang X; Xu K; Jin C; Tao L; Li L; Hou Y; Su X; Fang Q; Chen L; Liu H; Wang B; Yuan Z; Gao C; Zhou S; Sun Z; Zhao Y; Guan C; Stone GW; JACC Cardiovasc Interv; 2018 Feb; 11(3):260-272. PubMed ID: 29413240 [TBL] [Abstract][Full Text] [Related]
11. First experience of drug-coated balloons for treatment of bioresorbable vascular scaffold restenosis. Elwany M; Latini RA; Di Palma G; Orrego PS; Cortese B Cardiovasc Revasc Med; 2017; 18(7):482-486. PubMed ID: 28385555 [TBL] [Abstract][Full Text] [Related]
12. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy. Yamaji K; Brugaletta S; Sabaté M; Iñiguez A; Jensen LO; Cequier A; Hofma SH; Christiansen EH; Suttorp M; van Es GA; Sotomi Y; Onuma Y; Serruys PW; Windecker S; Räber L JACC Cardiovasc Interv; 2017 Sep; 10(18):1867-1877. PubMed ID: 28935079 [TBL] [Abstract][Full Text] [Related]
13. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW; JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836 [TBL] [Abstract][Full Text] [Related]
14. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961 [TBL] [Abstract][Full Text] [Related]
15. Myocardial Blood Flow and Coronary Flow Reserve During 3 Years Following Bioresorbable Vascular Scaffold Versus Metallic Drug-Eluting Stent Implantation: The VANISH Trial. Stuijfzand WJ; Schumacher SP; Driessen RS; Lammertsma AA; Bakker AL; Rijnierse MT; van Rossum AC; van de Ven PM; Nap A; Appelman Y; van Royen N; van Leeuwen MA; Lemkes JS; Raijmakers PG; Knaapen P JACC Cardiovasc Interv; 2019 May; 12(10):967-979. PubMed ID: 31029616 [TBL] [Abstract][Full Text] [Related]
16. Absorb bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in small vessel disease: A propensity matched analysis of COMPARE II, RAI, and MAASSTAD-ABSORB studies. Tarantini G; Masiero G; Barioli A; Paradies V; Vlachojannis G; Tellaroli P; Cortese B; di Palma G; Varricchio A; Ielasi A; Loi B; Steffenino G; Ueshima D; Mojoli M; Smits P Catheter Cardiovasc Interv; 2018 Aug; 92(2):E115-E124. PubMed ID: 29513403 [TBL] [Abstract][Full Text] [Related]
17. Serial intravascular ultrasound evaluation of the DESolve™ novolimus-eluting bioresorbable coronary scaffold system. Barreira G; Costa JR; Costa R; Staico R; Chamie D; Slhessarenko JR; Tanajura LF; Abizaid A; Sousa A; Abizaid A Catheter Cardiovasc Interv; 2018 Nov; 92(6):E368-E374. PubMed ID: 29521477 [TBL] [Abstract][Full Text] [Related]
18. Serial invasive imaging follow-up of the first clinical experience with the Magmaris magnesium bioresorbable scaffold. Tovar Forero MN; van Zandvoort L; Masdjedi K; Diletti R; Wilschut J; de Jaegere PP; Zijlstra F; Van Mieghem NM; Daemen J Catheter Cardiovasc Interv; 2020 Feb; 95(2):226-231. PubMed ID: 31033171 [TBL] [Abstract][Full Text] [Related]
19. Long-term invasive follow-up of the everolimus-eluting bioresorbable vascular scaffold: five-year results of multiple invasive imaging modalities. Simsek C; Karanasos A; Magro M; Garcia-Garcia HM; Onuma Y; Regar E; Boersma E; Serruys PW; van Geuns RJ EuroIntervention; 2016 Jan; 11(9):996-1003. PubMed ID: 25349042 [TBL] [Abstract][Full Text] [Related]
20. Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial. Baron SJ; Lei Y; Chinnakondepalli K; Vilain K; Magnuson EA; Kereiakes DJ; Ellis SG; Stone GW; Cohen DJ; JACC Cardiovasc Interv; 2017 Apr; 10(8):774-782. PubMed ID: 28427593 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]